Enliven Therapeutics Azioni (NASDAQ: ELVN)

Ultime notizie per Enliven Therapeutics (NASDAQ:ELVN) Azioni

Enliven Therapeutics

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics Inc

Jones Trading analyst Soumit Roy maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy and lowers the price target from $36 to $27.

News

Price Target

Analyst Ratings

ELVN

Jones Trading Maintains Buy on Enliven Therapeutics, Lowers Price Target to $27

WIIM

Enliven Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.

HC Wainwright &amp; Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy and raises the price target from $39 to $40.

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $40

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.49) by 16.33 percent. This is a 5.56 percent decrease over losses of $(0.54) per share from the same period last year.

Earnings

Earnings Misses

Enliven Therapeutics Q1 EPS $(0.57) Misses $(0.49) Estimate

Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs
ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff
Presentation at EHA will include updated data with additional patients and longer treatment duration
Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET
BOULDER, Colo., May 14, 2025 /PRNewswire/ --&nbsp;Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) in an abstract accepted for an oral presentation at the European Hematology Association (EHA) 2025 Congress taking place June 12-15 in Milan, Italy, and virtually. Updated data will be presented during an oral presentation at the conference on Friday, June 13, at 5 p.m. CEST/11 a.m. ET. Enliven management will host a webcast and conference call to discuss the data on Friday, June 13, at 7:30 p.m. CEST/1:30 p.m. ET.

Enliven Therapeutics Announces Updated Data From Phase 1 ENABLE Clinical Trial Evaluating ELVN-001 In Patients With CML In Abstract Accepted For Oral Presentation At EHA 2025 Congress

U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday.
Shares of The Greenbrier Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) fell sharply in today's pre-market trading as the company <a href="https://www.benzinga.com/quote/GBX/earnings">posted downbeat results for its second quarter.</a>
Greenbrier reported quarterly earnings of $1.56 per share which missed the analyst consensus estimate of $1.78 per share. The company reported quarterly sales of $762.100 million which missed the analyst consensus estimate of $898.530 million.
Greenbrier shares dipped 3.9% to $43.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) shares dipped 29.8% to $8.10 in today's pre-market trading after the company reported preliminary first quarter 2025 financial results.</li>
<li>Collective Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNL#NYSE">CNL</a>) declined 12.2% to $7.31 in pre-market trading.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 11.2% to $2.70 in pre-market trading after gaining over 7% on Monday.</li>
<li>PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) dipped 11% to $16.02 in pre-market trading.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) fell 7.5% to $3.2100 in pre-market trading.</li>
<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) dipped 7.1% to $8.51 in pre-market trading. Celcuity recently reported a year-over-year decrease in fourth-quarter EPS results.</li>
<li>RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) fell 5.9% to $100.40 in pre-market trading following weaker-than-expected quarterly results.</li>
<li>Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) fell 4.5% to $8.52 in pre-market trading.</li>
<li>Enliven Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) declined 3.8% to $17.20 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678688/dow-falls-for-3rd-session-amid-trumps-tariff-threats-as-apple-tesla-decline-greed-index-remains-in-extreme-fear-zone">Dow Falls For 3rd Session Amid Trump&#8217;s Tariff Threats As Apple, Tesla Decline: Greed Index Remains In &#8216;Extreme Fear&#8217; Zone</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

CELC

CVRX

INNV

MAZE

PRTC

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

HC Wainwright &amp; Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy and raises the price target from $37 to $39.

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $39

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 2.13 percent increase over losses of $(0.47) per share from the same period last year.

Earnings Beats

Enliven Therapeutics Q4 2024 GAAP EPS $(0.46) Beats $(0.52) Estimate

BTIG analyst Justin Zelin initiates coverage on Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy rating and announces Price Target of $42.

Initiation

BTIG Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $42

Baird analyst Colleen Kusy maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Outperform and raises the price target from $32 to $40.

Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent.

Enliven Therapeutics Q3 2024 GAAP EPS $(0.48) Beats $(0.49) Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Brian Skorney initiated coverage on Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with an Outperform rating and announced a price target of $25. Alumis shares closed at $11.23 on Wednesday. <a href="https://www.benzinga.com/quote/alms/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Soumit Roy initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy rating and announced a price target of $36. Enliven Therapeutics shares closed at $28.39 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See</a><a href="https://www.benzinga.com/quote/ELVN/analyst-ratings"> </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Swayampakula Ramakanth initiated coverage on Intensity Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) with a Buy rating and announced a price target of $5. Intensity Therapeutics shares closed at $3.05 on Wednesday. <a href="https://www.benzinga.com/quote/INTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer analyst Jay Olson initiated coverage on Terns Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) with an Outperform rating and announced a price target of $17. Terns Pharma shares closed at $6.89 on Wednesday. <a href="https://www.benzinga.com/quote/TERN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie initiated coverage on Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Neutral rating and announced a price target of $30. Braze shares closed at $32.00 on Wednesday. <a href="https://www.benzinga.com/quote/BRZE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ALMS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31113725/image-328-1024x495.png" alt="" class="wp-image-624229" style="width:550px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31113725/image-328-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31113725/image-328-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31113725/image-328-768x371.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31113725/image-328.png 1238w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>

ALMS

BRZE

INTS

TERN

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Jones Trading analyst Soumit Roy initiates coverage on Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy rating and announces Price Target of $36.

Jones Trading Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $36

Most of us have heard the dictum &quot;the trend is your friend.&quot; And this is undeniably the key to success when it comes to short-term investing or trading. But it isn&#39;t easy to ensure the sustainability of a trend and profit from it.
Often, the direction of a stock&#39;s price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it&#39;s important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going.
Investors looking to make a profit from stocks that are currently on the move may find our &quot;Recent Price Strength&quot; screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
<h2>Enliven Therapeutics, Inc.</h2>
(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elvn#NASDAQ">ELVN</a>) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for &quot;trend&quot; investors.
A solid price increase over a period of 12 weeks reflects investors&#39; continued willingness to pay more for the potential upside in a stock. ELVN is quite a good fit in this regard, gaining 26.8% over this period.
However, it&#39;s not enough to look at the price change for around three months, as it doesn&#39;t reflect any trend reversal that might have happened in a shorter time frame. It&#39;s important for a potential winner to maintain the price trend. A price increase of 25.1% over the past four weeks ensures that the trend is still in place for the stock of this company.
Moreover, ELVN is currently trading at 96.2% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock&#39;s near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
Another factor that confirms the company&#39;s fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock&#39;s near-term price performance.
So, the price trend in ELVN may not reverse anytime soon.
<a href="https://www.zacks.com/stock/news/2349711/enliven-therapeutics-inc-elvn-is-a-great-choice-for-trend-investors-here-s-why?cid=CS-BENZ-FT-tale_of_the_tape|recent_price_strength_screen-2349711">To read this article on Zacks.com click here.</a>

Biotech

Small Cap

General

Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why

HC Wainwright &amp; Co. analyst Robert Burns reiterates Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy and maintains $37 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Enliven Therapeutics, Maintains $37 Price Target

Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference &nbsp;
Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs
ELVN-001 remains well-tolerated with no dose reductions reported&nbsp;with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff
BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that has failed, or the patient is intolerant to or not a candidate for, available therapies known to be active for treatment of their CML (<a href="https://www.globenewswire.com/Tracker?data=7W5qBB0cMOZ3r3yHQ7lQqZKIjvg_18OVCDoV-Kb0LpJ3hpeCkVBbk0obODJZVX9ox2u3bkgl6VCVJxYSUcxpNL643m__t8O6CyJ1jsVsEl-3GjPDcAGESnmY1BuFwZGVdiAfqYOm0cYyqgS6CnLinw==">NCT05304377</a>) at the European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference.
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with CML.

Enliven Therapeutics Announces Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia; Reported Cumulative MMR Rate Of 44% (8/18) By 24 Weeks, With Stable Or Deepening Responses Between Weeks 12 And 24, Which Continues To Compare Favorably To Precedent Phase 1 Trials Of Approved BCR::ABL1 TKIs

Enliven Therapeutics shares are trading higher after the company provided more details regarding the presentation of its updated ELVN-001 Phase1a data of ESH-iCML at the 26th annual John Goldman Conference on CML.

Enliven Therapeutics Announces Details Regarding Presentation Of Updated ELVN-001 Phase 1a Data As ESH-iCMLf 26th Annual John Goldman Conference On CML

HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) and noted the company as an emerging biotech company developing next-gen precision-oriented small molecules for solid and <a target="_blank" href="https://www.benzinga.com/quote/ELVN" rel="noreferrer noopener">liquid tumor indications</a>.
Enliven&#8217;s pipeline includes:
<ul>
<li>ELVN-001— a tyrosine kinase inhibitor (TKI) targeting mutant BCR::ABL. HC Wainwright highlights that ELVN-001 could meaningfully improve on existing TKI drugs used in chronic myelogenous leukemia, with applicability across multiple lines of therapy.</li>
<li>In April, the company released proof of concept data from the Phase 1 trial of ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or <a href="https://www.benzinga.com/general/biotech/24/04/38208363/enliven-therapeutics-shares-first-look-at-safety-clinical-activity-of-lead-program" target="_blank" rel="noreferrer noopener">intolerant to available TKIs</a>.</li>
<li>ELVN-001 achieved a cumulative major molecular response (MMR) rate of 44% (7/16) by 12 weeks and demonstrated responses in patients with prior exposure to asciminib and who were TKI-resistant.</li>
<li>ELVN-002 is being evaluated in combination with trastuzumab plus chemotherapy or as monotherapy in HER2-driven malignancies within non-small cell lung, colorectal, and metastatic breast cancer, among others.</li>
</ul>
The analyst initiates with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/ELVN/analyst-ratings" rel="noreferrer noopener">price target of $37</a>.
CML is a chronic disease requiring multiple years of continuous treatment. Patients frequently switch therapies due to liabilities of the existing approved drugs, including poor tolerability due to off-target effects and inability to dose to maximal efficacy.
Six approved drugs—Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Gleevec (imatinib), Scemblix (asciminib), and Tasigna (nilotinib), Bristol-Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Sprycel (dasatinib), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Bosulif (bosutinib), and Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) Iclusig (ponatinib)—generate over $6 billion in annual sales, with each drug bringing in around $500 million. Some even achieve peak annual sales of up to $2 billion despite competition from generic versions.
HC Wainwright analyst projects that positioning ELVN-001 as a third-line treatment could surpass $500 million in peak annual sales.
ELVN-002 has the potential to address unmet needs in HER2-mutant NSCLC, CRC, and mBC, where current treatments have limitations. It could challenge competitors like Pfizer&#8217;s Tukysa and tap into the growing post-AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Enhertu market, with sales possibly reaching hundreds of millions.
While Enliven focuses on precision oncology, its target market is broader than that of past agents like Bristol-Myers&#8217; Augtyro (repotrectinib) and Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Rozlytrek (entrectinib).
Price Action: ELVN stock is up 7.32% at $23.01 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>.</li>
</ul>

Health Care

RHHBY

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

HC Wainwright &amp; Co. analyst Robert Burns initiates coverage on Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy rating and announces Price Target of $37.

Comments

Enliven Therapeutics

Notizie

Ultime notizie per Enliven Therapeutics (NASDAQ:ELVN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO